您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Dupilumab
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Dupilumab
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CAS NO:1190264-60-8
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
50mg电议
100mg电议

产品名称
REGN-668
SAR-231893
产品介绍
Dupilumab (REGN-668) 是针对 IL-4 受体α (IL-4Rα) 的完全人类单克隆抗体,可抑制IL-4IL-13信号转导,显着改善中度至重度特应性皮炎。
生物活性

Dupilumab (REGN-668) is a fully human mAb toIL-4 receptorα (IL-4Rα)that inhibits bothIL-4andIL-13signaling, markedly improved moderate-to-severe atopic dermatitis[1].

IC50& Target[1]

IL-4

 

IL-13

 

体外研究
(In Vitro)

Dupilumab suppressed mRNA expressions of genes related to activation of T cells, DCs, eosinophils, inflammatory pathways, and TH2-inducing chemokines in skin lesions. No significant reduction in IL-17A or IL-22 levels is detected, but large reductions in expression of IL-17–related genes, such as elafin (PI3), IL23p19/IL23A, and S100A8 and trends for suppression (CXCL1 and S100A7) are found with 300 mg of Dupilumab[1].
Major suppressions of hyperplasia-related genes (eg, K16) and reductions in expression of S100A genes are evident with 300 mg of Dupilumab by using microarrays and qRT-PCR. The changes in other critical epidermal alterations in severe atopic dermatitis (AD) skin are also measured, including significant increases in claudin and lipid product levels with 300 mg of Dupilumab. A trend of dose-dependent increases in expression of differentiation genes (LOR and FLG) is observed after adjusting for suppression of epidermal hyperplasia, as demonstrated by K16 reductions with Dupilumab[1].

Clinical Trial
性状

Liquid

CAS 号

1190264-60-8

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.